Tenax Therapeutics falls after heart drug misses late-stage study goal
10/08/2026 12:15
BUZZ-Tenax Therapeutics falls after heart drug misses late-stage study goal ** Shares of drug developer Tenax TENX.O fall 83.9% to $2.16 premarket
** Co's experimental heart drug fails to meet the main goal of a late-stage study
** TENX was testing TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or HFpEF
** Up to last close, stock up 10.3% YTD
(Reporting by Puyaan Singh)